[go: up one dir, main page]

UA115250C2 - Фармацевтичні комбінації - Google Patents

Фармацевтичні комбінації

Info

Publication number
UA115250C2
UA115250C2 UAA201505167A UAA201505167A UA115250C2 UA 115250 C2 UA115250 C2 UA 115250C2 UA A201505167 A UAA201505167 A UA A201505167A UA A201505167 A UAA201505167 A UA A201505167A UA 115250 C2 UA115250 C2 UA 115250C2
Authority
UA
Ukraine
Prior art keywords
pharmaceutically acceptable
combination
protein kinase
acceptable salt
pharmaceutical combinations
Prior art date
Application number
UAA201505167A
Other languages
English (en)
Inventor
Дейл ПОРТЕР
Керолайн Емері
Луцзянь ТАНЬ
Падмаджа Йерраміллі-Рао
Original Assignee
Новартіс Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новартіс Аг filed Critical Новартіс Аг
Publication of UA115250C2 publication Critical patent/UA115250C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Винахід стосується фармацевтичної комбінації, що включає сполуку-інгібітор РКС, яка являє собою 3-(1H-індол-3-іл)-4-[2-(4-метилпіперазин-1-іл)-хіназолін-4-іл]-1H-пірол-2,5-діон або його фармацевтично прийнятну сіль, та сполуку-інгібітор МЕК, яка являє собою (2-гідроксіетоксі)-амід 6-(4-бром-2-фторфеніламіно)-7-фтор-3-метил-3Н-бензімідазол-5-карбонової кислоти або його фармацевтично прийнятну сіль; застосування такої комбінації в лікуванні проліферативних захворювань.
UAA201505167A 2012-11-29 2013-11-26 Фармацевтичні комбінації UA115250C2 (uk)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261731174P 2012-11-29 2012-11-29
US201261731555P 2012-11-30 2012-11-30
US201361755520P 2013-01-23 2013-01-23
PCT/US2013/071852 WO2014085381A1 (en) 2012-11-29 2013-11-26 Pharmaceutical combinations

Publications (1)

Publication Number Publication Date
UA115250C2 true UA115250C2 (uk) 2017-10-10

Family

ID=49753513

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201505167A UA115250C2 (uk) 2012-11-29 2013-11-26 Фармацевтичні комбінації

Country Status (16)

Country Link
US (1) US9446043B2 (uk)
EP (1) EP2925366B1 (uk)
JP (1) JP6437444B2 (uk)
CN (1) CN104812415A (uk)
AU (1) AU2013352379B2 (uk)
BR (1) BR112015012497B1 (uk)
CA (1) CA2892578C (uk)
DK (1) DK2925366T3 (uk)
ES (1) ES2669248T3 (uk)
HU (1) HUE037618T2 (uk)
NZ (1) NZ708802A (uk)
PL (1) PL2925366T3 (uk)
RU (1) RU2674995C2 (uk)
TR (1) TR201806682T4 (uk)
UA (1) UA115250C2 (uk)
WO (1) WO2014085381A1 (uk)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201904851D0 (en) 2019-04-05 2019-05-22 Katholieke Univ Leven Melanoma treatment
US11086278B2 (en) 2019-08-29 2021-08-10 Inventus Holdings, Llc Adaptive system monitoring using incremental regression model development
WO2022221586A1 (en) * 2021-04-15 2022-10-20 Ideaya Biosciences, Inc. Combination therapy comprising a pkc inhibitor and a mek inhibitor
EP4577309A2 (en) * 2022-08-26 2025-07-02 Ideaya Biosciences, Inc. Methods of treating uveal melanoma with a pkc inhibitor
GB202408598D0 (en) * 2024-06-14 2024-07-31 Edvince Ab Combination treatments
GB202408599D0 (en) * 2024-06-14 2024-07-31 Vasopharma Ab Combination treatments

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5489608A (en) 1989-12-21 1996-02-06 Goedecke Aktiengesellschaft Indolocarbazole derivatives and the use thereof
US5475085A (en) 1991-02-07 1995-12-12 Molecumetics, Ltd. Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same
AU687909B2 (en) 1993-12-07 1998-03-05 Eli Lilly And Company Protein kinase C inhibitors
ATE456367T1 (de) 1993-12-23 2010-02-15 Lilly Co Eli Proteinkinase c inhibitoren
US5545636A (en) 1993-12-23 1996-08-13 Eli Lilly And Company Protein kinase C inhibitors
JP3348859B2 (ja) 1995-11-20 2002-11-20 イーライ・リリー・アンド・カンパニー プロテインキナーゼｃインヒビター
DZ3401A1 (fr) 2000-07-19 2002-01-24 Warner Lambert Co Esters oxygenes d'acides 4-iodophenylamino benzhydroxamiques
US6645970B2 (en) 2000-11-07 2003-11-11 Novartis Ag Indolylmaleimide derivatives
BRPI0115193B1 (pt) 2000-11-07 2016-08-09 Novartis Ag derivados de indolilmaleimida, processo para preparação dos mesmos, bem como composição farmacêutica que os compreende
TWI338685B (en) 2002-03-13 2011-03-11 Array Biopharma Inc N3 alkylated benzimid azole derivatives as mek inhibitors
AR039209A1 (es) 2002-04-03 2005-02-09 Novartis Ag Derivados de indolilmaleimida
US6930093B2 (en) * 2003-07-10 2005-08-16 Valeant Research & Development Use of ribofuranose derivatives against inflammatory bowel diseases
MXPA06014478A (es) 2004-06-11 2007-03-21 Japan Tobacco Inc Derivados de 5-amino-2, 4, 7-trioxo-3, 4, 7, 8-tetrahidro -2h-pirido[2, 3-d]pirimidina y compuestos relacionados para el tratamiento del cancer.
KR20080019236A (ko) 2005-05-18 2008-03-03 어레이 바이오파마 인크. Ｍｅｋ의 헤테로시클릭 억제제 및 그의 사용 방법
JP2009501172A (ja) 2005-07-11 2009-01-15 ノバルティス アクチエンゲゼルシャフト インドリルマレイミド誘導体

Also Published As

Publication number Publication date
WO2014085381A1 (en) 2014-06-05
JP6437444B2 (ja) 2018-12-12
BR112015012497A8 (pt) 2019-10-01
US20150306101A1 (en) 2015-10-29
AU2013352379A1 (en) 2015-06-11
NZ708802A (en) 2019-09-27
EP2925366A1 (en) 2015-10-07
BR112015012497A2 (pt) 2017-07-11
CN104812415A (zh) 2015-07-29
CA2892578A1 (en) 2014-06-05
RU2674995C2 (ru) 2018-12-14
CA2892578C (en) 2021-01-12
RU2015124954A (ru) 2017-01-11
BR112015012497B1 (pt) 2022-05-17
JP2016501222A (ja) 2016-01-18
HK1215789A1 (en) 2016-09-15
DK2925366T3 (en) 2018-06-06
EP2925366B1 (en) 2018-02-21
HUE037618T2 (hu) 2018-09-28
ES2669248T3 (es) 2018-05-24
US9446043B2 (en) 2016-09-20
PL2925366T3 (pl) 2018-08-31
TR201806682T4 (tr) 2018-06-21
AU2013352379B2 (en) 2018-09-06

Similar Documents

Publication Publication Date Title
MX2016008362A (es) Combinaciones farmaceuticas.
NZ703940A (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
MX360045B (es) Combinaciones farmacéuticas de un inhibidor de cdk4/6 y un inhibidor de b-raf.
MX2014010590A (es) Terapia de combinacion para trastornos proliferativos.
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
MX2021004639A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos.
HK1201065A1 (en) Novel quinoxaline inhibitors of pi3k
WO2015054619A3 (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
MX2017014338A (es) Seleccion dirigida de pacientes para el tratamiento con derivados de cortistatina.
MX2015005798A (es) Terapia de combinacion.
HK1198869A1 (en) Combination treatments for hepatitis c
WO2015095834A3 (en) Cancer treatments using erk1/2 and bcl-2 family inhibitors
MX2014002471A (es) Combinaciones sinergicas de los inhibidores de p13k y mek.
UA115250C2 (uk) Фармацевтичні комбінації
WO2013071056A3 (en) Combination drug therapy for the treatment of solid tumors
AR093182A1 (es) Metodo para tratar el sobrepeso o la obesidad
IN2015DN00528A (uk)
NZ602807A (en) 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one and an mtor inhibitor
MX2014014817A (es) Compuestos para el tratamiento de inflamacion y dolor.
HK1225969A1 (zh) 利用低剂量的拉喹莫德治疗克隆氏病
PH12013501638A1 (en) (5s,8s)-3-(4`-chlor-3`-fluor-4-methlybiphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one (compound a) for treatment
MX2015015475A (es) Combinacion de un inhibidor de la quinasa pi3 con paclitaxel para uso en el tratamiento o prevencion de un cancer de cabeza y cuello.